HRP20150641T1 - Anti -cd38 humana antitijela i njihove uporabe - Google Patents
Anti -cd38 humana antitijela i njihove uporabe Download PDFInfo
- Publication number
- HRP20150641T1 HRP20150641T1 HRP20150641TT HRP20150641T HRP20150641T1 HR P20150641 T1 HRP20150641 T1 HR P20150641T1 HR P20150641T T HRP20150641T T HR P20150641TT HR P20150641 T HRP20150641 T HR P20150641T HR P20150641 T1 HRP20150641 T1 HR P20150641T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- amino acid
- fragment according
- epitope
- seq
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 15
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 6
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 208000014951 hematologic disease Diseases 0.000 claims 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Claims (18)
1. Humano ili humanizirano antitijelo ili njegov fragment koje/koji sadrži antigen-vežuću regiju koji se specifično veže za epitop CD38, pri čemu epitopa sadrži jednu ili više aminokiselinskih ostataka sadržanih u jednom ili više aminokiselinskih nizova uzetih sa popisa aminokiselinskih nizova 44-66, 82-94, 142-154, 148-164, 158-170, ili 192-206 CD38 (SEQ ID NO: 22).
2. Antitijelo ili njegov fragment prema patentnom zahtjevu 1, pri čemu epitopa sadrži jedan ili više aminokiselinskih ostataka sadržanih u aminokiselinskim nizovima 44-66 ili 148-164 CD38 (SEQ ID NO: 22).
3. Antitijelo ili njegov fragment prema patentnom zahtjevu 1, pri čemu epitopa sadrži jedan ili više aminokiselinskih ostataka sadržanih u aminokiselinskom nizu 192-206 CD38 (SEQ ID NO: 22).
4. Antitijelo ili njegov fragment prema patentnom zahtjevu 1, pri čemu epitopa sadrži jedan ili više aminokiselinskih ostataka sadržanih u aminokiselinskim nizovima 82-94, ili 158-170 CD38 (SEQ ID NO: 22).
5. Antitijelo ili njegov fragment prema patentnom zahtjevu 1, pri čemu epitopa sadrži jedan ili više aminokiselinskih ostataka sadržanih u aminokiselinskim nizovima 82-94 ili 142-154 CD38 (SEQ ID NO: 22).
6. Antitijelo ili njegov fragment prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je epitopa linearna epitopa.
7. Antitijelo ili njegov fragment prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je epitopa konformacijska epitopa.
8. Antitijelo ili njegov fragment prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je antitijelo IgG.
9. Antitijelo ili njegov fragment prema patentnom zahtjevu 8, pri čemu je antitijelo IgG1.
10. Antitijelo ili njegov fragment prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu je antitijelo sintetičko humano antitijelo.
11. Nukleinska kiselina koja kodira antitijelo ili njegov fragment prema bilo kojem od patentnih zahtjeva 1 do 10.
12. Vektor koji sadrži nukleinsku kiselinu prema patentnom zahtjevu 11.
13. Stanica koja sadrži vektor prema patentnom zahtjevu 12.
14. Stanica prema patentnom zahtjevu 13, pri čemu je navedena stanica bakterijska stanica ili stanica sisavca.
15. Farmaceutska kompozicija koja sadrži humano antitijelo ili njegov funkcionalni fragment prema bilo kojem od patentnih zahtjeva 1 do 10 i farmaceutski prihvatljiv nosač ili ekscipijent.
16. Uporaba humanog antitijela ili njegovog funkcionalnog fragmenta prema bilo kojem od patentnih zahtjeva 1 do 10 za pripremu farmaceutske kompozicije za tretman hematološke bolesti.
17. Humano antitijelo ili njegov funkcionalni fragment prema bilo kojem od patentnih zahtjeva 1 do 10 za uporabu u postupku za tretman hematološke bolesti.
18. Uporaba prema patentnom zahtjevu 16 ili humano antitijelo ili njegov funkcionalni fragment za uporabu prema patentnom zahtjevu 17, pri čemu je hematološka bolest multipli mijelom, kronična limfocitna leukemija, kronična mijelogena leukemija, akutna mijelogena leukemija ili akutna limfocitna leukemija.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54191104P | 2004-02-06 | 2004-02-06 | |
| US54758404P | 2004-02-26 | 2004-02-26 | |
| US55394804P | 2004-03-18 | 2004-03-18 | |
| US59901404P | 2004-08-06 | 2004-08-06 | |
| US61447104P | 2004-10-01 | 2004-10-01 | |
| EP11196172.8A EP2511297B1 (en) | 2004-02-06 | 2005-02-07 | Anti-CD38 human antibodies and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150641T1 true HRP20150641T1 (hr) | 2015-07-17 |
Family
ID=37054659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150641TT HRP20150641T1 (hr) | 2004-02-06 | 2015-06-15 | Anti -cd38 humana antitijela i njihove uporabe |
Country Status (19)
| Country | Link |
|---|---|
| EP (3) | EP2511297B1 (hr) |
| JP (4) | JP2008504013A (hr) |
| KR (2) | KR20140066259A (hr) |
| BR (1) | BRPI0507489A (hr) |
| CY (1) | CY1116458T1 (hr) |
| DK (2) | DK2511297T3 (hr) |
| ES (2) | ES2541489T3 (hr) |
| HK (1) | HK1097859A1 (hr) |
| HR (1) | HRP20150641T1 (hr) |
| HU (1) | HUE025369T2 (hr) |
| IL (1) | IL177242A (hr) |
| ME (1) | ME02245B (hr) |
| NO (1) | NO20063986L (hr) |
| NZ (1) | NZ548990A (hr) |
| PL (1) | PL2511297T3 (hr) |
| PT (1) | PT2511297E (hr) |
| RS (1) | RS54056B1 (hr) |
| SG (1) | SG142330A1 (hr) |
| WO (1) | WO2005103083A2 (hr) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| BRPI0507489A (pt) | 2004-02-06 | 2007-07-10 | Morphosys Ag | anticorpos humanos de anti-cd38 e para os seus usos |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| AU2006301446B2 (en) | 2005-10-12 | 2012-06-07 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| HUE049832T2 (hu) | 2005-12-29 | 2020-10-28 | Janssen Biotech Inc | Humán anti-IL-23 ellenanyagok, készítmények, eljárás és alkalmazások |
| EP2039766A4 (en) * | 2006-06-05 | 2010-06-16 | Univ Hiroshima | IMMUNOCOMPETENT CELL HAVING ANTI-CD38 ANTIBODY ON ITS SURFACE |
| CA2664740C (en) | 2006-09-26 | 2021-11-16 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| AU2013209322A1 (en) * | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| EP2191841A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| WO2010079189A1 (en) | 2009-01-09 | 2010-07-15 | Morphosys Ag | Display vectors and methods and uses thereof |
| WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
| MX350540B (es) | 2010-09-27 | 2017-09-08 | Morphosys Ag | Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl. |
| JP2013543382A (ja) * | 2010-10-05 | 2013-12-05 | 第一三共株式会社 | 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体 |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| KR102037541B1 (ko) | 2011-10-28 | 2019-10-29 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| EP2900232B1 (en) | 2012-09-25 | 2017-11-15 | MorphoSys AG | Combinations and uses thereof |
| US9486547B2 (en) | 2012-11-05 | 2016-11-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
| JP2014117191A (ja) * | 2012-12-13 | 2014-06-30 | Fisheries Research Agency | リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途 |
| AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| PT2992013T (pt) * | 2013-04-29 | 2020-03-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| EP3176185A1 (en) | 2013-11-04 | 2017-06-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| RS59907B1 (sr) * | 2014-03-28 | 2020-03-31 | Xencor Inc | Bispecifična antitela koja se vezuju za cd38 i cd3 |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| WO2015195555A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10106620B2 (en) | 2014-06-16 | 2018-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| EA037749B1 (ru) | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN116333153A (zh) | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| BR112017011749A2 (pt) | 2014-12-04 | 2018-05-15 | Janssen Biotech Inc | anticorpos anti-cd38 para o tratamento de leucemia mieloide aguda |
| JP7068825B2 (ja) | 2015-04-08 | 2022-05-17 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ３８に結合する抗体治療剤 |
| JP7160533B2 (ja) | 2015-05-13 | 2022-10-25 | モルフォシス・アーゲー | 多発性骨髄腫（ｍｍ）の処置 |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| HUE051246T2 (hu) | 2015-05-30 | 2021-03-01 | Molecular Templates Inc | Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| MY193727A (en) | 2015-06-24 | 2022-10-27 | Janssen Biotech Inc | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PT3827845T (pt) | 2015-11-03 | 2022-07-08 | Janssen Biotech Inc | Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações |
| AU2017226960B2 (en) | 2016-03-04 | 2024-03-21 | Morphosys Ag | Clinical assessment of M-protein response in multiple myeloma |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| JP2019521171A (ja) | 2016-07-20 | 2019-07-25 | ヒブリジェニクス・エスアー | 抗ｃｄ３８薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用 |
| AU2018280868A1 (en) | 2017-06-08 | 2020-01-02 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| CA3067311A1 (en) | 2017-06-20 | 2018-12-27 | Sorrento Therapeutics, Inc. | Cd38 antibody drug conjugate |
| JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
| EP3668543A1 (en) | 2017-08-16 | 2020-06-24 | Black Belt Therapeutics Limited | Cd38 antibody |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| AU2018348093A1 (en) * | 2017-10-10 | 2020-05-28 | Sanofi | Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| US20230158070A1 (en) | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810320D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
| WO2020081881A2 (en) | 2018-10-17 | 2020-04-23 | Janssen Biotech, Inc. | Method of providing subcutaneous administration of anti-cd38 antibodies |
| CN113395979A (zh) | 2018-11-20 | 2021-09-14 | 詹森生物科技公司 | 用抗il-23特异性抗体治疗银屑病的安全且有效的方法 |
| EP3893841A1 (en) | 2018-12-14 | 2021-10-20 | MorphoSys AG | Antibody formulations |
| GB201900530D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for CD38 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| WO2020187718A1 (en) | 2019-03-15 | 2020-09-24 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| WO2020261219A1 (en) | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
| MX2021015433A (es) | 2019-07-02 | 2022-06-08 | Hutchinson Fred Cancer Res | Vectores ad35 recombinantes y mejoras de la terapia génica relacionadas. |
| WO2021260657A1 (en) | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CN114075283A (zh) * | 2020-08-12 | 2022-02-22 | 三生国健药业（上海）股份有限公司 | 结合人cd38的抗体、其制备方法和用途 |
| CN114195893A (zh) * | 2020-09-17 | 2022-03-18 | 百奥泰生物制药股份有限公司 | 抗整联蛋白抗体或抗原结合片段及其应用 |
| GB202016331D0 (en) | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
| WO2022137186A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| AU2022208200A1 (en) | 2021-01-14 | 2023-07-20 | Morphosys Ag | Anti-cd38 antibodies and their uses |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| US20220387488A1 (en) | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| AR125852A1 (es) | 2021-05-12 | 2023-08-16 | Crispr Therapeutics Ag | Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
| US20230136301A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
| CN116547307A (zh) * | 2021-12-03 | 2023-08-04 | 南京维立志博生物科技有限公司 | 结合cd38的抗体及其用途 |
| WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) * | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| JP2000316578A (ja) * | 1999-05-12 | 2000-11-21 | Bml Inc | 糖尿病発症危険因子の検出方法 |
| JP4312403B2 (ja) | 1999-07-20 | 2009-08-12 | モルフォシス・アクチェンゲゼルシャフト | （ポリ）ペプチド／タンパク質を、ジスルフィド結合を介してバクテリオファージ粒子に表示させる新規方法 |
| EP1174440A1 (en) * | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| ATE484522T1 (de) * | 2001-04-24 | 2010-10-15 | Bayer Corp | Menschliche antikörper gegen timp-1 |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| BRPI0507489A (pt) * | 2004-02-06 | 2007-07-10 | Morphosys Ag | anticorpos humanos de anti-cd38 e para os seus usos |
| US20090123950A1 (en) | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
| WO2007053577A2 (en) | 2005-10-31 | 2007-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| JP2012022417A (ja) * | 2010-07-12 | 2012-02-02 | Humony Co Ltd | 電子請求処理サービスシステム及び該電子請求処理サービスシステム用のアプリケーション |
| JP6257929B2 (ja) * | 2013-06-13 | 2018-01-10 | 東芝メディカルシステムズ株式会社 | Ｘ線コンピュータ断層撮影装置 |
-
2005
- 2005-02-07 BR BRPI0507489-4A patent/BRPI0507489A/pt not_active Application Discontinuation
- 2005-02-07 HU HUE11196172A patent/HUE025369T2/en unknown
- 2005-02-07 ES ES11196172.8T patent/ES2541489T3/es active Active
- 2005-02-07 PT PT111961728T patent/PT2511297E/pt unknown
- 2005-02-07 KR KR1020147011314A patent/KR20140066259A/ko not_active Application Discontinuation
- 2005-02-07 DK DK11196172.8T patent/DK2511297T3/en active
- 2005-02-07 EP EP11196172.8A patent/EP2511297B1/en not_active Revoked
- 2005-02-07 ES ES05769690.8T patent/ES2541436T3/es active Active
- 2005-02-07 RS RS20150390A patent/RS54056B1/en unknown
- 2005-02-07 EP EP05769690.8A patent/EP1720907B1/en active Active
- 2005-02-07 PL PL11196172T patent/PL2511297T3/pl unknown
- 2005-02-07 EP EP15151492.4A patent/EP2915820A1/en not_active Ceased
- 2005-02-07 JP JP2006551957A patent/JP2008504013A/ja not_active Withdrawn
- 2005-02-07 KR KR1020137028482A patent/KR20130126747A/ko not_active IP Right Cessation
- 2005-02-07 SG SG200803286-4A patent/SG142330A1/en unknown
- 2005-02-07 NZ NZ548990A patent/NZ548990A/en not_active IP Right Cessation
- 2005-02-07 DK DK05769690.8T patent/DK1720907T3/en active
- 2005-02-07 WO PCT/IB2005/002476 patent/WO2005103083A2/en active Application Filing
-
2006
- 2006-08-02 IL IL177242A patent/IL177242A/en active IP Right Grant
- 2006-09-05 NO NO20063986A patent/NO20063986L/no not_active Application Discontinuation
-
2007
- 2007-05-07 HK HK07104826.5A patent/HK1097859A1/xx unknown
-
2012
- 2012-02-03 JP JP2012022417A patent/JP5926568B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-05 JP JP2015000102A patent/JP2015110597A/ja active Pending
- 2015-06-15 HR HRP20150641TT patent/HRP20150641T1/hr unknown
- 2015-07-02 CY CY20151100576T patent/CY1116458T1/el unknown
-
2016
- 2016-05-17 ME MEP-2015-350A patent/ME02245B/me unknown
- 2016-06-03 JP JP2016111794A patent/JP2016164198A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130126747A (ko) | 2013-11-20 |
| JP2015110597A (ja) | 2015-06-18 |
| CY1116458T1 (el) | 2017-03-15 |
| NZ548990A (en) | 2009-06-26 |
| EP1720907A2 (en) | 2006-11-15 |
| RS54056B1 (en) | 2015-10-30 |
| BRPI0507489A (pt) | 2007-07-10 |
| DK1720907T3 (en) | 2015-06-15 |
| ME02245B (me) | 2015-10-30 |
| EP1720907B1 (en) | 2015-04-08 |
| WO2005103083A8 (en) | 2006-10-05 |
| ES2541436T3 (es) | 2015-07-20 |
| WO2005103083A2 (en) | 2005-11-03 |
| HK1097859A1 (en) | 2007-07-06 |
| KR20140066259A (ko) | 2014-05-30 |
| JP5926568B2 (ja) | 2016-05-25 |
| JP2012116856A (ja) | 2012-06-21 |
| EP2511297B1 (en) | 2015-04-08 |
| SG142330A1 (en) | 2008-05-28 |
| WO2005103083A3 (en) | 2006-11-16 |
| ES2541489T3 (es) | 2015-07-21 |
| JP2016164198A (ja) | 2016-09-08 |
| HUE025369T2 (en) | 2016-02-29 |
| EP2915820A1 (en) | 2015-09-09 |
| DK2511297T3 (en) | 2015-06-15 |
| IL177242A0 (en) | 2006-12-10 |
| NO20063986L (no) | 2006-11-06 |
| PL2511297T3 (pl) | 2015-08-31 |
| JP2008504013A (ja) | 2008-02-14 |
| PT2511297E (pt) | 2015-08-24 |
| IL177242A (en) | 2011-09-27 |
| EP2511297A1 (en) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150641T1 (hr) | Anti -cd38 humana antitijela i njihove uporabe | |
| HRP20200918T1 (hr) | Modificirane mutirane fuzijske molekule interferonskog antitijela | |
| HRP20160485T1 (hr) | Anti-mezotelinska protutijela i njihova uporaba | |
| AR107902A2 (es) | Anticuerpos anti-cd37 | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| AU2006218454B2 (en) | Humanized L243 antibodies | |
| UA94060C2 (ru) | Моноклональное антитело, которое специфически связывает alk-1 | |
| JP2016135783A5 (hr) | ||
| JP2019520809A5 (hr) | ||
| JP7455897B2 (ja) | 抗ｐｄ１および抗ｃｔｌａ４抗体 | |
| RU2010129558A (ru) | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С АЛЬФА-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173 | |
| JP2008541733A5 (hr) | ||
| ES2687706T3 (es) | Anticuerpos útiles en la inmunización pasiva contra la gripe | |
| HRP20131085T1 (hr) | Uporaba antagonistiäśkih anti-cd40 monoklonskih antitijela | |
| CN106243225B (zh) | 新型抗-pd-l1抗体 | |
| RU2005132389A (ru) | Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами | |
| UA83791C2 (ru) | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 | |
| JP2013121353A5 (hr) | ||
| SG193805A1 (en) | Compositions and methods of use for therapeutic antibodies | |
| CN112218892A (zh) | 新型抗ctla-4抗体多肽 | |
| EP2780372A1 (en) | Bi-specific antibodies for medical use | |
| JP2021501566A5 (hr) | ||
| CN112236456B (zh) | 新型双特异性pd-1/lag-3抗体分子 | |
| KR20160131073A (ko) | Lg4-5에 대해 특이적인 항-라미닌4 항체 | |
| RU2012137380A (ru) | Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи |